GSA Capital Partners LLP Buys New Position in Bruker Corporation $BRKR

Posted by Brenda Bartman on Aug 20th, 2026

GSA Capital Partners LLP bought a new stake in shares of Bruker Corporation (NASDAQ:BRKR – Free Report) in the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor bought 11,552 shares of the medical research company’s stock, valued at approximately $695,000.

A number of other hedge funds and other institutional investors have also recently modified their holdings of the company. Orbis Allan Gray Ltd acquired a new position in shares of Bruker in the 2nd quarter worth approximately $192,735,000. Price T Rowe Associates Inc. MD lifted its holdings in Bruker by 2,963.4% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 2,366,520 shares of the medical research company’s stock valued at $111,488,000 after buying an additional 2,289,269 shares during the period. AQR Capital Management LLC lifted its holdings in Bruker by 125.3% in the second quarter. AQR Capital Management LLC now owns 3,326,820 shares of the medical research company’s stock valued at $137,065,000 after buying an additional 1,850,215 shares during the period. Franklin Resources Inc. boosted its position in Bruker by 317.7% during the fourth quarter. Franklin Resources Inc. now owns 2,309,404 shares of the medical research company’s stock valued at $108,796,000 after acquiring an additional 1,756,460 shares during the last quarter. Finally, Millennium Management LLC boosted its position in Bruker by 222.6% during the fourth quarter. Millennium Management LLC now owns 1,839,587 shares of the medical research company’s stock valued at $86,663,000 after acquiring an additional 1,269,316 shares during the last quarter. Institutional investors and hedge funds own 79.52% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research firms have recently weighed in on BRKR. UBS Group set a $60.00 price objective on Bruker in a research report on Wednesday, June 24th. Zacks Research upgraded Bruker from a “hold” rating to a “strong-buy” rating in a research report on Tuesday, August 4th. Leerink Partners raised their target price on Bruker from $60.00 to $70.00 and gave the stock an “outperform” rating in a research note on Tuesday, July 7th. Wolfe Research initiated coverage on Bruker in a report on Monday, June 1st. They issued a “peer perform” rating for the company. Finally, Weiss Ratings raised Bruker from a “sell (d)” rating to a “sell (d+)” rating in a research note on Wednesday, June 3rd. Two research analysts have rated the stock with a Strong Buy rating, six have given a Buy rating, four have assigned a Hold rating and two have issued a Sell rating to the stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $56.64.

Check Out Our Latest Analysis on Bruker

Bruker Price Performance

Shares of NASDAQ BRKR opened at $58.65 on Thursday. The stock has a market cap of $8.94 billion, a price-to-earnings ratio of -83.79, a PEG ratio of 1.74 and a beta of 1.28. The company has a debt-to-equity ratio of 0.76, a quick ratio of 0.92 and a current ratio of 1.85. Bruker Corporation has a fifty-two week low of $28.53 and a fifty-two week high of $65.30. The firm’s 50-day simple moving average is $58.46 and its 200 day simple moving average is $47.28.

Bruker (NASDAQ:BRKR – Get Free Report) last issued its quarterly earnings data on Tuesday, August 4th. The medical research company reported $0.49 EPS for the quarter, topping analysts’ consensus estimates of $0.38 by $0.11. The firm had revenue of $838.50 million during the quarter, compared to analyst estimates of $853.57 million. Bruker had a positive return on equity of 12.47% and a negative net margin of 2.35%.The company’s revenue for the quarter was up 5.2% on a year-over-year basis. During the same period in the previous year, the company posted $0.32 EPS. Bruker has set its FY 2026 guidance at 2.100-2.150 EPS. As a group, research analysts anticipate that Bruker Corporation will post 2.12 earnings per share for the current fiscal year.

Bruker Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Wednesday, October 7th. Investors of record on Monday, September 21st will be given a dividend of $0.05 per share. The ex-dividend date of this dividend is Monday, September 21st. This represents a $0.20 annualized dividend and a dividend yield of 0.3%. Bruker’s payout ratio is presently -28.57%.

About Bruker

(Free Report)

Bruker Corporation, founded in 1960 by physicist Günther Laukien and headquartered in Billerica, Massachusetts, is a leading developer and manufacturer of high-performance scientific instruments and analytical solutions. The company designs systems that enable molecular and materials research across academic, governmental, and industrial laboratories.

Bruker’s product portfolio encompasses nuclear magnetic resonance (NMR) spectrometers for molecular structure and dynamics studies, mass spectrometry platforms for proteomics and metabolomics, X-ray diffraction and scattering instruments for crystallography and materials characterization, atomic force and scanning probe microscopes for nanoscale surface analysis, as well as preclinical imaging systems such as micro-CT and MRI scanners.

In addition to hardware, Bruker provides software suites, applications support, training services, and long-term maintenance agreements to ensure optimal instrument performance.